To evaluate the ability of 20 mgkgweek BMN 110 and 20 mgkgqow BMN 110 compared with placebo to enhance endurance in patients with MPS IVA as measured by an increase in the number of meters walked in the 6-minute walk 6MW test from baseline to Week 24
Data and Resources
- A Phase 3 Randomized Double-Blind Placebo-Controlled Multinational Clinical Study to Evaluate the Efficacy and Safety of 20 mgkgweek and 20 mgkgevery other week BMN 110 in Patients with Mucopolysaccharidosis IVA Morquio A Syndromejson
To evaluate the ability of 20 mgkgweek BMN 110 and 20 mgkgqow BMN 110...
|Release Date|| |
License Not Specified
|Public Access Level|| |